Innovative drug stocks are broadly trending higher, with ZAI LAB (09688) surging 14.32% to HK$16.61, WUXI XDC (02268) climbing 9.48% to HK$60.65, and WUXI BIO (02269) advancing 6.19% to HK$43.94. METIS TECHBIO-P (07666) rose 6.05% to HK$11.05, while ASCLETIS-B (01672) gained 5.89% to HK$10.79.

On the news front, several innovative drug companies have recently released earnings-related announcements. From BeiGene posting a net profit increase of over six times year-on-year to WuXi AppTec significantly raising its full-year revenue guidance, and Innovent Biologics and Rongchang Biologics each delivering on their growth narratives, the innovative drug supply chain is entering a resonance window of "earnings delivery plus dense catalysts."

Additionally, according to data from the National Medical Products Administration, China's innovative drug out-licensing deals reached 81 in the first half of the year, with a total transaction value of approximately $110 billion, hitting 80% of the full-year 2025 target and setting a new mid-year record high.

Notably, clinical data disclosures at top-tier overseas medical conferences are expected to become short-term core catalysts. The WCLC has already published abstract titles, with full data set for release on August 19. The ESC Annual Meeting at the end of August will focus on reporting key clinical trial results in the cardiovascular field.

Bohai Securities believes that August marks the interim earnings reporting season, and recommends first focusing on sectors driven by earnings performance. Secondly, the firm maintains a long-term bullish view on the development trend of domestic innovative drugs, citing rising industry sentiment and ongoing overseas expansion. As academic conferences are held successively, clinical data readings are expected to provide a dense stream of catalysts.